Welcome to our dedicated page for Xtl Biopharmaceu SEC filings (Ticker: XTLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XTL Biopharmaceuticals Ltd. filings document foreign-private-issuer current reports, capital-structure actions, governance matters, and material events involving its ADSs and ordinary shares. Recent Form 6-K reports cover ADS-to-ordinary-share ratio disclosures, shareholder meeting results, authorized share-capital amendments, director elections, private-placement approvals, and material agreements.
The filing record also documents Nasdaq listing notifications, the company's IP portfolio identity, and court-ordered liquidation proceedings involving its wholly owned subsidiary The Social Proxy Ltd. These disclosures frame XTL's public-company status, shareholder approvals, securities structure, and risks tied to operating continuity and strategic transactions.
XTL Biopharmaceuticals Ltd. has signed a binding letter of intent with Beyond Air, Inc. to acquire Beyond Air’s approximately 85% stake in NeuroNOS Ltd., an Israeli private company developing small‑molecule treatments for autism spectrum disorder, Alzheimer’s disease, brain cancers, and other neurological conditions. If completed, XTL would issue American Depositary Shares so that Beyond Air holds 19.99% of XTL’s outstanding share capital at closing, grant three‑year warrants to help maintain that stake, pay an upfront US$1,000,000 in cash, and pay up to US$5,500,000 in development milestones or, in some cases, a single US$4,000,000 payment.
The LOI also provides for commercial milestone payments between US$2,000,000 and US$12,500,000 linked to net sales of the first NeuroNOS product, and contemplates an offer for other NeuroNOS shareholders to exchange their remaining 15% stake for XTL shares. To help fund the deal and the upfront cash, XTL’s board and audit committee approved a concurrent private placement of up to US$2,000,000 at about US$0.53 per ADS, at a 20% discount, subject to closing of the transaction and various corporate, regulatory, shareholder, and due‑diligence conditions.
XTL Biopharmaceuticals Ltd. reports that Tal Klinger, Chief Executive Officer of its wholly owned Israeli subsidiary Social Proxy Ltd., and Roee Klinger, the subsidiary’s Chief Technology Officer, have resigned from their positions effective immediately as of December 11, 2025. The company states that it is evaluating next steps for the management of Social Proxy Ltd. and plans to provide further updates when appropriate.
XTL Biopharmaceuticals Ltd. reported a leadership change in its finance team. Chief Financial Officer Itay Weinstein will resign effective December 11, 2025, and the company states his resignation is not due to any disagreement with management.
To replace him, the board appointed Niv Segal as Chief Financial Officer. Segal is a CPA with over 12 years of senior financial management experience, including serving as CFO of G.S. Innplay Labs, where he led a $300M acquisition by Playtika, and CFO of Beach Bum, where he managed its $700M acquisition process. He previously served as Group Corporate Controller at Gix Ltd. and began his career at PwC Israel.
XTL Biopharmaceuticals Ltd. announced a board change. Effective October 21, 2025, Doron Turjeman resigned from the Board of Directors due to personal reasons. The company stated his resignation was not the result of any disagreement with the company or its management. Noam Band, the Company’s Chief Executive Officer, was appointed to the Board of Directors in his place, effective immediately.
XTL is an IP portfolio company that owns 100% of The Social Proxy Ltd., a web data company, and has sublicensed an IP portfolio around hCDR1 for treating lupus (SLE). The company trades on Nasdaq (XTLB) and the TASE (XTLB.TA).